Pentwater Capital Management LP Rapt Therapeutics, Inc. Transaction History

Pentwater Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$16.28 - $24.6 $407,000 - $615,000	25,000 New	25,000 $495,000
Q1 2022 May 16, 2022	SELL	$17.02 - $40.22 $1.96 Million - $4.63 Million	-115,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$29.86 - $39.47 $298,600 - $394,700	10,000 Added 9.52%	115,000 $3.57 Million
Q2 2021 Aug 16, 2021	BUY	$17.99 - $40.02 $1.35 Million - $3 Million	75,000 Added 250.0%	105,000 $3.34 Million
Q1 2021 May 17, 2021	SELL	$16.0 - $24.46 $160,000 - $244,600	-10,000 Reduced 25.0%	30,000 $666,000
Q3 2020 Nov 16, 2020	BUY	$21.6 - $37.5 $75,772 - $131,550	3,508 Added 9.61%	40,000 $1.29 Million
Q2 2020 Aug 14, 2020	BUY	$14.16 - $32.85 $17,289 - $40,109	1,221 Added 3.46%	36,492 $1.06 Million
Q1 2020 May 15, 2020	BUY	$11.86 - $48.86 $418,314 - $1.72 Million	35,271 New	35,271 $750,000

104

27.1M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $24.9M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Pentwater Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Pentwater Capital Management LP with notifications on news.